8-K: PharmaCyte Boosts TNF Stake, Backs LightSpeed Crypto Tech

Sentiment:

Strategic Investment and Technology License 5 September 2025 4:05 PM

📋All filings for Pharmacyte Biotech, INC

PharmaCyte Biotech invests an additional $3 million in TNF Pharmaceuticals to support its new license for a breakthrough light-speed computing platform aimed at cryptocurrency and blockchain applications.

Delay expectedThe effectiveness of the resale registration statement for TNF's shares is subject to an 'Effectiveness Deadline' which can be extended if the SEC conducts a full review (from 60 to 90 calendar days for initial filing, or 30 to 60 calendar days for additional filings).The exercise of TNF Warrants and conversion of TNF Preferred Shares are contingent on 'Stockholder Approval' from TNF, which has a deadline of November 16, 2025, but can be extended if not obtained, requiring additional semi-annual meetings until approval is secured.Any increase in a holder's Maximum Percentage of beneficial ownership (from 4.99% to 9.99%) is not effective until the sixty-first (61st) day after notice is delivered to the Company.

Capital raisePharmaCyte Biotech is purchasing Series H convertible preferred stock and warrants from TNF Pharmaceuticals for an aggregate purchase price of $3,000,000 in a private placement, representing a capital raise for TNF Pharmaceuticals.

Summary

PharmaCyte Biotech (PMCB) invested an additional $3 million in TNF Pharmaceuticals, Inc. (TNF) through a private placement.
This investment supports TNF's recent acquisition of a license with LightSolver, Ltd. for a "revolutionary processing accelerator" designed to expedite compute-sensitive computations.
LightSolver's technology aims to reduce energy output by 90% and outperform conventional GPUs, quantum computing, and high-performance computing in speed and efficiency.
TNF Pharmaceuticals plans to change its name and ticker symbol to align with its new strategy, focusing on cryptocurrency mining and blockchain applications.
PharmaCyte's investment consists of TNF's newly designated Series H convertible preferred stock and warrants.
The Series H Preferred Shares are convertible into 600,000 TNF Common Shares at an initial conversion price of $5.00 per share.
The warrants allow for the purchase of up to 600,000 TNF Common Shares at an exercise price of $5.00 per share.
The Preferred Shares accrue dividends at 7.0% per annum, compounded monthly, payable in cash, with a default rate of 15% upon a Triggering Event.
TNF is obligated to file a resale registration statement for 200% of the TNF Conversion Shares and TNF Warrant Shares within 15 calendar days after the closing and ensure its effectiveness by the specified deadline.
PharmaCyte Biotech maintains a strong financial position with over $55 million in total assets as of April 30, 2025.

Sentiment

Score: 7

Explanation: The investment represents a strategic diversification into a high-growth, innovative sector with promising technology. While there are inherent risks associated with new technology adoption and market volatility in crypto/blockchain, PharmaCyte's strong capital position and the potential for significant energy efficiency and performance gains from LightSolver's platform suggest a positive long-term outlook, assuming successful execution and market acceptance.

Positives

PharmaCyte Biotech is diversifying its investment portfolio by increasing its stake in TNF Pharmaceuticals, gaining exposure to the cryptocurrency and blockchain sectors.
The investment supports TNF's acquisition of a license for LightSolver's technology, which promises significant energy efficiency (90% reduction) and performance improvements over existing computing methods for cryptocurrency and blockchain.
TNF's strategic pivot into cryptocurrency mining and blockchain, powered by innovative technology, could open new high-growth avenues and potentially disrupt the market.
PharmaCyte remains well-capitalized with over $55 million in total assets, providing financial stability for future opportunities and strategic investments.
The Series H Preferred Shares offer a 7.0% annual dividend, providing a steady income stream from the investment for PharmaCyte.

Negatives

The success of TNF's new strategy in cryptocurrency and blockchain, and the effectiveness of LightSolver's technology in this application, are subject to significant market and technological risks.
PharmaCyte's investment in TNF is through a private placement, meaning liquidity for its stake may be limited until the resale registration statement for the underlying shares is effective.
The conversion and exercise of the preferred shares and warrants are subject to TNF's stockholder approval and Nasdaq listing rules, which could delay full realization of the investment's potential.
The 'full ratchet' price-based adjustment for the warrants could lead to significant dilution for TNF's existing common shareholders if future equity is issued at a lower price.
TNF Pharmaceuticals is subject to various covenants and potential Triggering Events, which, if breached, could lead to mandatory redemption obligations at a premium, impacting TNF's financial health.

Risks

Technological Adoption Risk: The success of TNF's new strategy is dependent on the successful utilization of LightSolver's computing technology in cryptocurrency applications, which is unproven at scale.
Market Volatility Risk: The cryptocurrency and blockchain markets are highly volatile, which could significantly impact the value and prospects of TNF's new business direction.
Regulatory Risk: Changes in regulations pertaining to cryptocurrency mining and blockchain could adversely affect TNF's operations and profitability.
Execution Risk: TNF's ability to successfully pivot its strategy, change its name/ticker, and integrate the new technology into its operations carries inherent execution risks.
Dilution Risk: The 'full ratchet' price-based adjustment on the warrants and potential adjustments to the conversion price of the preferred shares could lead to significant dilution for TNF's common stockholders.
Liquidity Risk: The preferred shares and warrants are not registered under the Securities Act of 1933, and their resale is dependent on TNF filing and maintaining an effective registration statement, which may not occur in a timely manner.
Stockholder Approval Risk: The conversion and exercise of the securities are subject to TNF's stockholder approval to comply with Nasdaq listing standards, which may not be obtained in a timely manner or at all, potentially limiting PharmaCyte's ability to convert or exercise its securities.
Financial Covenants Risk: TNF is subject to various affirmative and negative covenants, including maintaining a cash minimum of $500,000, and breaches could trigger redemption rights for PharmaCyte at a premium.
Default Risk: Triggering Events, such as suspension of trading, conversion/delivery failures, or defaults on indebtedness exceeding $250,000, could lead to mandatory redemption obligations for TNF at a premium, potentially straining its finances.

Future Outlook

PharmaCyte Biotech continues to evaluate additional opportunities to expand and diversify its investment portfolio. TNF Pharmaceuticals is expected to change its name and ticker symbol to support its new strategy, which will focus on applying LightSolver's computing technology to cryptocurrency mining and blockchain.

Management Comments

PharmaCyte Biotech remains well-capitalized with significant cash resources, with total assets of over $55 million, as of April 30, 2025.
The Company continues to evaluate additional opportunities to expand and diversify its investment portfolio.

Industry Context

This investment positions PharmaCyte Biotech to gain exposure to the rapidly evolving and high-growth sectors of cryptocurrency mining and blockchain technology. TNF Pharmaceuticals' adoption of LightSolver's 'light-speed computing platform' suggests a move towards more energy-efficient and powerful solutions, potentially setting a new benchmark in an industry often criticized for its high energy consumption. This aligns with broader industry trends seeking sustainable and advanced computational methods for digital asset operations.

Comparison to Industry Standards

LightSolver's technology claims a 90% reduction in energy output and superior speed/efficiency compared to conventional GPUs, quantum computing, and high-performance computing, which, if proven, would significantly exceed current industry standards for crypto mining and blockchain infrastructure.
The investment in a 'breakthrough light speed computing platform' suggests a move beyond standard ASIC miners or GPU farms, aiming for a competitive edge in computational power and cost-effectiveness.
LightSolver's recognition by Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies and as a 2025 World Economic Forum Technology Pioneer indicates its technology is considered cutting-edge and potentially disruptive within the broader computing and data center industry.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
New Preferred Stock Series	TNF Pharmaceuticals authorized a new series of Series H Convertible Preferred Stock with specific rights, preferences, and limitations.	2025-09-04	Introduces a new class of equity with senior dividend and liquidation preferences over common stock, and specific voting rights for holders, potentially impacting common shareholder influence and returns.
Stockholder Approval Requirement	TNF Pharmaceuticals is required to obtain stockholder approval for the issuance of securities exceeding certain Nasdaq thresholds, with a deadline of November 16, 2025, and subsequent semi-annual meetings if not met.	2025-09-02	Ensures compliance with exchange rules and provides existing stockholders a say on potentially dilutive issuances, but introduces a potential delay risk for full conversion/exercise of the new securities.
Covenants on TNF Pharmaceuticals	TNF Pharmaceuticals is subject to affirmative and negative covenants, including restrictions on indebtedness, liens, restricted payments, asset transfers, and a cash minimum of $500,000.	2025-09-02	Imposes financial discipline and protects the interests of the preferred shareholders by limiting certain corporate actions and ensuring liquidity, potentially restricting TNF's operational flexibility.
Voting Rights for Preferred Stock	Holders of Series H Preferred Shares are entitled to vote with common stockholders on an as-converted basis, with specific minimum conversion price for voting calculation.	2025-09-04	Grants significant voting influence to preferred shareholders, particularly the 'Required Holders' who can consent to amendments or waivers of key provisions, potentially shifting control dynamics.

Stakeholder Impact

Shareholders (PharmaCyte Biotech): Potential for increased shareholder value through diversification into high-growth tech sectors (cryptocurrency/blockchain) and exposure to innovative, energy-efficient computing technology.
Shareholders (TNF Pharmaceuticals): Potential for significant dilution from the issuance of preferred stock and warrants, especially with 'full ratchet' anti-dilution provisions. However, the capital raise and strategic pivot could enhance long-term growth prospects.
Employees (TNF Pharmaceuticals): Strategic shift into a new industry may lead to changes in skill requirements and potential restructuring, but also new opportunities in a growing field.
Customers (TNF Pharmaceuticals): New focus on cryptocurrency mining and blockchain will target a different customer base than traditional pharmaceuticals.
Creditors (TNF Pharmaceuticals): The covenants and redemption rights associated with the Series H Preferred Stock provide certain protections, but the new business venture introduces new operational and market risks.

Next Steps

TNF Pharmaceuticals to file a resale registration statement for the TNF Conversion Shares and TNF Warrant Shares within 15 calendar days after the Closing Date.
TNF Pharmaceuticals to use best efforts to have the registration statement declared effective by the Effectiveness Deadline.
TNF Pharmaceuticals to hold a special meeting of stockholders by November 16, 2025, to obtain Stockholder Approval for the issuance of securities in compliance with Nasdaq listing standards.
If Stockholder Approval is not obtained by the deadline, TNF must hold additional stockholder meetings semi-annually until approval is secured.
TNF Pharmaceuticals is expected to change its name and ticker symbol to reflect its new strategy in cryptocurrency mining and blockchain.
PharmaCyte Biotech will continue to evaluate additional opportunities to expand and diversify its investment portfolio.

Key Dates

Date	Description
2024-01-01	Start date for internal control and data privacy compliance review period mentioned in the Securities Purchase Agreement.
2025-04-30	Date of PharmaCyte Biotech's total assets reported at over $55 million.
2025-06-30	Date of existing Permitted Indebtedness reflected on TNF's balance sheet.
2025-08-19	Date TNF's Quarterly Report on Form 10-Q was filed with the SEC, including balance sheet for Permitted Indebtedness.
2025-09-01	TNF Pharmaceuticals' Board of Directors adopted the resolution to create Series H Convertible Preferred Stock.
2025-09-02	PharmaCyte Biotech entered into the Securities Purchase Agreement with TNF Pharmaceuticals and issued a press release announcing the transaction.
2025-09-04	Closing of the purchase of TNF Preferred Shares and TNF Warrants occurred; TNF filed the Certificate of Designations of Series H Convertible Preferred Stock with the State of Delaware.
2025-09-05	Date of signing of the 8-K report by PharmaCyte Biotech's CFO.
2025-10-01	First Dividend Date for Series H Convertible Preferred Stock.
2025-11-16	Deadline for TNF Pharmaceuticals to hold a Stockholder Meeting to approve the issuance of securities in compliance with Nasdaq rules.
2027-03-02	Maturity Date for Series H Convertible Preferred Stock.

Recommendation

hold

The investment by PharmaCyte Biotech into TNF Pharmaceuticals' new light-speed computing platform for cryptocurrency and blockchain is a significant strategic pivot with high potential upside due to the innovative technology and high-growth market. However, it also introduces substantial execution risk, market volatility exposure, and potential dilution for TNF's existing common shareholders. PharmaCyte's strong cash position provides a buffer, but the success of this venture is unproven. A 'hold' recommendation is appropriate for investors to monitor the progress of TNF's strategic shift, the adoption and performance of LightSolver's technology, and the realization of the anticipated energy efficiency and speed benefits before making further investment decisions. The long-term implications of this diversification are still unfolding.

Keywords

PharmaCyte Biotech, TNF Pharmaceuticals, LightSolver, Cryptocurrency, Blockchain, Light Speed Computing, Processing Accelerator, Private Placement, Convertible Preferred Stock, Warrants, SEC Filing, Investment Diversification, Technology Pioneer, Nasdaq, PMCB, TNFA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.